List of Biotech, Pharmaceutical & Life Sciences companies in North Carolina - 213

410 Medical is a medical device company dedicated to developing innovative products that enable clinicians to improve care for critically ill patients. LifeFlow® PLUS, 410's recently approved product, is designed to enhance the speed and efficiency of volume resuscitation, improving care for patients with life-threatening conditions such as sepsis, hemorrhage and cardiac arrest.

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL acquired all the patents and IP rights from TherapyEdge, Inc. in 2005 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. COVID-19: CE mark (07/2020)

AccuGenomics is a biotechnology company that specializes in a unique spike-in control technology to enhance the accuracy of clinical sequencing tests for low abundance biomarkers and infectious pathogens.

Adaptin Bio, is a pioneering biotechnology company dedicated to revolutionizing drug delivery. Our focus is on developing innovative technologies that enhance how medications and other therapeutic compounds reach their target destinations within the body. Our core mission is to overcome a major hurdle in medicine: ensuring effective delivery of drugs to specific tissues.

Develops a rapid leukocyte differential instrument is used to screen for infections, allergies, and blood-related cancers including leukemia.

Adrenas Therapeutics is a company that was created with a single mission: to work with scientists, physicians, and patients in developing a gene therapy for people affected by CAH. Adrenas is a subsidiary of BridgeBio, a public company dedicated to finding, developing, and delivering breakthrough medicines for genetic diseases to patients as quickly and safely as possible.

Adroit Pharmaceutical Development was founded to efficiently identify new formulations and process technologies for our clients. We also work with clients to identify and correct problems with their existing formulations and processes.

AgBiomeis usingknowledge of the crop microbiome and an extensive network of field-sampling partners to build a proprietary microbial strain collection that is both diverse and large—larger, in fact, than the major public strain collections. Unlike many programs, which only use metagenomics surveys, the AgBiome platform is focused on true isolated microbial strains, which provideinsight into the genomic composition of crop-associated microbes. The company uses this collection as a resource for discovering new biologicals and trait genes.Existing microbial classification systems based on 16S rDNA sequences or other fingerprinting technologies are imprecise—microbes that are classified as ‘the same’ often differ by hundreds of genes. AgBiome uses proprietary algorithms based on whole genome sequence to classify organisms in their collection. This allows the company to measure the true diversity of plant-associated microbes at the gene level—and genes determine function and performance. The company has also applied our whole-genome methods to their straincollection.

Alcami is a pharmaceutical CDMO that offers contract development and manufacturing services for the healthcare and biotechnology industries.

ARC specializes in mass culturing of sensitive marine and freshwater microalgae that are challenging to grow on a large scale. We are also experts in finding the proper medias for difficult to culture species and isolating species from wild samples. Our main group of focus are dinoflagellates, but we have recently expanded our services to include diatoms, such as Haslea sp., and freshwater species, such as the green algae Oophila sp. ARC also provides toxin analysis, DNA extraction and sequencing, photomicrographs, and HPLC pigment analysis. Feel free to contact us at arc.uncwilmington@gmail.com or view our website for service pricing and available strains.

The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man. These immune responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell) immune responses, confirming the promising data we have obtained in over a decade of intensive pre-clinical work with this vector platform.

Areteia Therapeutics is a clinical stage biotechnology company committed to putting respiratory patients in better control of their disease—and back in control of their lives. The company's purpose is to develop and deliver novel inflammation modulating therapies to improve the lives of patients with respiratory diseases. Areteia Therapeutics is dedicated to advancing the treatment of respiratory diseases, including asthma and eosinophilic asthma, through innovative research and development.

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

At Arrivo, we strive to set a new standard in drug development that starts with the selection of drug candidates and runs throughout clinical development. Our approach and decision-making has delivered a history of excellent returns and product successes that makes us the trusted partner for industry and investors.

Ascletis is an innovative R&D driven biotech listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.

Asensus Surgical is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.Senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: https://www.senhance.com/indications.

Aseptic Technologies develops, manufactures and markets equipment that guarantee optimal sterility assurance level and complies with latest regulatory requirements, while simplifying the validation and operation processes in the safest way. Aseptic Technologies improves the quality of aseptic operations by providing user-oriented and really innovative state-of-the-art equipment and services to the pharmaceutical industry.

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for congestive heart failure, Huntington’s disease, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson’s disease, and Pompe disease. AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, Scotland, the company has generated hundreds of proprietary capsids and promoters, several of which have entered pre-clinical and clinical testing. Learn more at askbio.com. Vision - Pioneering science to create transformative molecular medicines. Mission - Lead innovative science and drive clinical outcomes to transform people's lives. Values: • Be a Pioneer. We are not afraid of the impossible and to innovate to make gene therapies accessible to those in need. • Cultivate Collaboration. Strive to be the best teammate, actively listen, openly communicate, and embrace diverse points of view. • Embrace Responsibility. We are humbled by the enormity of our mission. We hold a relentless commitment to advance science and clinical outcomes for our patients, families, and caregivers. • Raise the Bar. Continuously drive improvements and efficiencies. Seek and provide constructive feedback. Have a bias for learning and action. • Act with Uncompromising Integrity. Be honest, transparent, and committed to doing what’s right in every situation. Make clear commitments and follow through.

At Asterra Labs, we are pharmaceutical scientists and industry veterans with a passion to innovate, develop, and manufacture a pharmaceutical-grade line of safe, beneficial wellness products and alternative medicines.

Atlantic Fish Company is working to make cultivate seafood. Cells are harvested from the fish and fed nutrients in a bioreactor. Scaffolding is used to give the cells a structure to grow on and produce the texture of a whole fish fillet. The end product is REAL seafood, grown directly from fish cells.

Atom Bioworks is a startup company that specializes in DNA nanostructures.

Atsena Therapeutics is a clinical-stage gene therapy company developing novel treatments for inherited forms of blindness. The company has two clinical-stage programs, ATSN-201 for X-linked retinoschisis (XLRS) and ATSN-101 for GUCY2D-associated Leber congenital amaurosis (LCA1). ATSN-201, which leverages the company’s novel spreading capsid AAV.SPR, is being evaluated in XLRS patients in a Phase I/II clinical trial known as the LIGHTHOUSE study. The company’s additional proprietary asset is ATSN-301, a dual AAV vector-based gene therapy to prevent blindness from MYO7A-associated Usher syndrome (USH1B). Interim safety and efficacy data from the company’s ongoing Phase I/II clinical trial in patients with LCA1 have demonstrated ATSN-101 is well tolerated and clinically meaningful improvements in vision were observed 12 months post-treatment. Founded by ocular gene therapy pioneers Dr. Shannon Boye and Sanford Boye of the University of Florida, Atsena is based in North Carolina’s Research Triangle, an environment rich in gene therapy expertise.

About Auration Biotech, Inc Vision: To develop novel therapeutics for treatment of diseases of the ear, nose and throat. History: Founded in 2014 Founders: Benjamin F. McGraw, III, PharmD (Executive Chairman) Sanjay Chanda, PhD (Development Consultant) Peter Santa Maria, MBBS, PhD, FRACS (Chairman, SAB) Programs: AU-935 (HB-EGF), non-surgical repair of tympanic

Avazyme, Inc. a contract research solution provider, offering field and laboratory testing, product development, and expert consulting services to the agriculture and food industries. Avazyme's comprehensive services include food safety analyses for contaminants, pathogens, allergens, food quality and nutrition analysis, genetic trait testing, product safety, FDA Menu Labeling, pesticide residues, mycotoxin analysis, specialized studies for regulatory submission data packages, and a full spectrum of testing for product safety and product quality related to Industrial Hemp. Avazyme provides fast and reliable answers to ensure product safety and high product quality for consumable food, feed, cosmetics, nutraceutical Avazyme also offers comprehensive laboratory and "​in-brewery"​ services to craft breweries and local hops growers and maltsters. Most recently, Volker and his Avazyme team have been a strong supporter and testing partner for the fast-emerging Industrial Hemp Industry in North Carolina and the entire East Coast

Avicenna Biosciences was founded to solve the intractable challenges that previously stopped drug candidates in their tracks. We have created an ML-driven medicinal chemistry platform that makes Lead Optimization faster, cheaper, and more successful – transforming sub-optimal development candidates into life-saving drugs. The platform has seen rapid success in discovering the first orally available, CNS-penetrant ROCK inhibitors for the treatment of neurodegenerative diseases, with IND-enabling studies initiated just one year since the program kicked off.

Baebies Inc. is a growth-stage medical device company developing innovative products to enable early disease detection and multifunctional diagnostics for syndromic testing for children and adults. Guided by the vision that everyone deserves to be healthy, we aim to deliver ‘Any test. Anywhere. To Everyone.’ We deliver millions of tests globally every year to save lives and make lives better. Baebies is a pioneer in digital microfluidics technology, which maximizes diagnostic yield from low-volume samples. Baebies is headquartered in Durham, North Carolina, and our products are used in central laboratories and point-of-care settings around the world. Over 20 million tests delivered, and counting. Every test is a chance to save a life. Our current pipeline of test panels on the multifunctional FINDER platform include molecular (Respiratory panel - Flu A, Flu B, RSV, and SARS-CoV-2, STI panel - CT/NG/TV), coagulation (anti-factor Xa, aPTT), and chemistry (G6PD).

Bantam Pharmaceutical is a drug discovery company harnessing the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial dynamics, Bantam is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. Bantam is currently pursuing an IND application for Its lead candidate, BTM-3566, in B-cell malignancies. About BTM-3566 BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566’s anti-cancer mechanism of action is unique from any other therapeutic, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is currently underway and will be completed by Q1 2022.

BA Sciences is a cGMP compliant, FDA/DEA registered, ISO/IEC-17025:2017 certified analytical laboratory located in Salem, NH. BA provides testing services to Pharmaceutical, Biopharmaceutical and Medical Device companies worldwide including: Analytical Testing and Method Development, Microbiological Testing and Environmental Monitoring Services, Biologics, Stability Testing & ICH-compliant Storage, Impurities Testing, Advanced Therapeutics and Extractables & Leachables Studies.

Bedrock Therapeutics is an AAV gene therapy research and development company developing platform and disease specific technologies for the treatment of ocular, hematologic, and other diseases. Drs. Matt Hirsch, Chenwen Li, Bryan Sutton, and Brian Gilger are co-founders of Bedrock. Drs. Gilger and Hirsch oversee the de novo design and validation of ocular assets, and Drs. Li and Sutton oversee basics aspects of the various host immune responses to AAV vectors and protein engineering and design.

Purpose-built for organizations conducting clinical trials and observational studies, we leverage our AI-powered patient-matching platform and clinical expertise to optimize feasibility and speed up patient identification by extracting structured and unstructured data from electronic medical records (EMRs) that captures three times more trial criteria. Why: We believe sites are vital to the success of clinical trials. Empowering them to find the right patient for the right research at the right time is the focus of everything we do. What: We leverage our best-in-class technology and data expertise to detect more protocol-eligible candidates than traditional methods, so that site teams can focus on the parts of the job they actually love. How: We deliver an AI-powered software platform and support from clinical experts that enables our customers to find and match patients to available clinical research. With unbelievably fast and highly-accurate data extraction from electronic medical records (EMRs) we can capture three times more trial criteria - making trial participation more accessible and efficient.

Belhaven Biopharma is developing a portfolio of dry powder nasal medicines to provide convenient, safe, and rapid treatments in emergency situations

BioAgilytix is a biotechnology company that specializes in bioanalysis for the biopharmaceutical and life sciences industries.

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world. As world leaders in structure-guided drug design, we draw on the strengths and expertise of all our colleagues—from those of us in the field or behind the scenes in our labs, to others based in home offices and around the globe. To view our LinkedIn community guidelines, please visit bit.ly/BCRXGuidelines.

BioCytics via the Human Applications Lab is focused on bringing personalized oncology treatments to the market. BioCytics has an ongoing IRB-approved clinical trial (BioCytics 0001; NCT00571389) that allows for the collection and study of blood and tissue samples from consenting cancer patients. We are incubated within Carolina BioOncology - a preferred cancer treatment and Phase I drug testing facility. BioCytics was founded by Dr. John Powderly, MD, medical board certified oncologist and a certified physician investigator (CPI), who is also president of Carolina BioOncology Institute (CBOI).

Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world. We have launched our first product, ASPYRE-Lung, in the US and we have an extensive pipeline of novel products. Biofidelity has developed a novel molecular biology technology which enables genomic analysis for cancer diagnosis to be carried out locally, quickly and far more cost-effectively.

Biolink LifeSciences is a premier contract research organization offering a comprehensive range of services including synthesis, characterization, formulation development, and analytical services for small to large molecules for nearly all dosage forms. Our strength resides with our highly experienced team in synthetic chemistry, analytical method development & validation and formulation development to solve difficult problems.

Biomason is a unique biotechnology start-up manufacturing company with a natural process that will revolutionize the building and construction industry. Biomason employs natural microorganisms and chemical processes to manufacture biological cement-based masonry building materials.Biomasonmakes biocement by usingBacillus to hydrolyze urea. This process producesCO2, whichcombines with calcium ions to form calcium carbonate. This process binds particles of sand and rock together to make tiles.

BIOMILQ is a women-owned and science-led mammary biotechnology start-up leveraging its patented technology to produce functional cell-cultured human milk components outside the body. With the goal of bridging the gap between breast milk and infant formula, BIOMILQ aims to revolutionize early-life nutrition by bringing more of the benefits of breast milk to more babies.

BioSkryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.

BMG LABTECH is a leading developer and manufacturer of microplate reader instrumentation with a wide range of measurement methods. Microplate readers are used in the pharmaceutical and biotech industries, as well as in academic research establishments, for both basic research analysis and high-throughput screening. We focus solely on microplate readers and offers the most diverse selection of optical detection systems in conjunction with integrated liquid handling equipment. Our exceptional worldwide sales and support network is committed to bringing you innovative microplate reader technology with the reliability and quality that you expect from BMG LABTECH. The highest priority at BMG LABTECH is to have satisfied microplate reader customers! We succeed at this goal by not only offering excellent microplate readers but also providing personal customer support that not found at larger companies. Our support centers have teams of microplate reader development specialists ready to work with you and your applications to get the most out of your microplate reader. This close working relationship allows BMG LABTECH to completely understand your needs and to help develop our instruments to meet the changing needs of the microplate reader market. Imprint: https://www.bmglabtech.com/legal-notice/ Privacy Policy: https://www.bmglabtech.com/privacy-statement-linkedin/

Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.

Bryn Pharma is a privately held pharmaceutical company based in North Carolina. Primary focus is on the development and commercialization of innovative allergy products for the management of anaphylaxis. The mission of Bryn Pharma is to empower patients with a life-saving device that is small enough to comfortably fit in your pocket and easy to use in the event of an anaphylactic attack. Our intranasal delivery system will be an exciting alternative to epinephrine auto-injectors providing patients a needle-free option that is easy to use, portable, and affordable.

Caeregen Therapeutics discovers and develops novel therapies which repair, restore, and protect damaged and diseased tissues by reactivating the pathways and signaling which accompany normal cellular and tissue development. Our revolutionary regenerative medicine approaches have the potential to restore lost or degraded functioning to diseased tissue and organs.

Caidya is a multi-therapeutic clinical research organization (CRO) serving innovators worldwide. Focused on delivery excellence and an elevated customer experience, Caidya offers a wide range of clinical services and vast therapeutic expertise, supporting its partners from pre-IND strategy, through clinical development to submission and post-marketing surveillance. Caidya leverages industry-leading and proprietary clinical technology to ensure trial transparency and data-driven decision-making. Formed in 2021 following the combination of leading CROs, dMed and Clinipace, Caidya has nearly 1,800 employees in more than 30 countries throughout the world.

CAMAG is the world leader in High-Performance Thin-Layer Chromatography. We provide high-end instruments, tools and concepts for TLC/HPTLC. Additionally, we support our clients with training, technical and contract laboratory services. Wherever complex substance mixtures are analyzed (e.g. herbal, environmental or forensic samples), TLC/HPTLC often is an excellent alternative to GC and HPLC. Moreover, it has proven value as a solid quantitative analysis technique in quality assurance of food, pharmaceuticals and other industrial products. Since 1961, CAMAG is dedicated to the development and manufacturing of instruments, software and consumables for all steps of the TLC/HPTLC procedure. Our products are truly Swiss made and have an excellent reputation throughout the world.

Combination Therapy Pill - Cardiovascular

Carolina Liquid Chemistries (CLC) helps clinical laboratories of all sizes reduce reagent costs and get accurate, timely results. CLC is a leading provider of chemistry instruments and reagents for use in reference laboratories and clinical laboratories in hospitals, laboratories in physician offices, and veterinary facilities. CLC offers a complete line of clinical chemistry analyzers and over 100 general and toxicology (urine drug screen) reagents. CLC offers our branded line of reagents, instruments, services, training, and validation assistance. Our chemistry analyzers include: • CLC6410 • CLC1600 • CLC800 • CLC480/BiOLiS 24i We are a privately held, veteran-owned, ISO-certified company, and an FDA-registered manufacturer, re-packager, and re-labeler of chemistry analyzers and related products. For over 25 years, we have brought multiple reagents for a variety of chemistry instruments and reagents to market. We have served nearly 2,000 customers worldwide and are committed to helping laboratories reduce costs and get accurate, timely results.

Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company's cloneXplorer and proprietary nanowell plates uniquely integrates both phenotypic and genomic data at massive scale (up to 100,000s of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology. Learn more at www.celldom.com and follow the company's growth @celldominc on Twitter.

Lifechanging breakthroughs like cell and gene therapy are driving a medical revolution. But a lack of purpose-built development and manufacturing tools keeps these treatments from reaching more patients. At Charter Medical, we're on a mission to evolve single-use cell processing step-by-step with the needs of the biopharmaceutical innovators who count on us. With proven customization capabilities and an innovation roadmap that includes pioneering design and biomaterials. With industry-leading expertise and continuous improvement to simplify and standardize biomanufacturing systems so they can scale reliably. And with a deep commitment to responsiveness, collaboration and urgency. Because we know single-use advances are essential to helping our clients make revolutionary therapies more accessible to patients who need them – now.

At Chimerix, we are on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. With a focus in oncology, we are devoted to filling gaps in the treatment paradigm.

Citranvi Biosciences is a pre-clinical stage company engaged in the design and development of novel systems and tools for immunogenicity enhancement applicable to Vaccines Research and Development. We are developing innovative and proprietary vaccine technology platforms and products, using comprehensive structure-based vaccine design, broadly applicable to a variety of preventable disease targets, where there is an unmet global medical need.

CivaTech Oncology® designs innovative products that bring meaningful improvements to low dose rate brachytherapy. The CivaString® and CivaSheet™ can substantially reduce procedure time, provide homogeneous dose distribution and minimize trauma. Customizable CivaTech products ensure that radiation oncologists can deliver individualized, targeted therapy to treat cancer. http://www.civatechoncology.com/

CiVentiChem is a premier Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience serving the pharmaceutical and specialty chemical industries. We operate two facilities in India, specializing in medicinal chemistry, process chemistry, and the manufacturing of Regulatory Starting Materials (RSMs) and intermediates. Our team’s expertise allows us to support projects at every stage, from early drug discovery to full-scale commercial production. In 2019, we successfully sold our GMP kilo-lab in Cary, North Carolina, to Sterling Pharma, further focusing our efforts on expanding our global manufacturing capabilities. In 2024, we made significant investments to increase our production capacity, enabling us to manage programs ranging from gram-scale synthesis to multi-ton manufacturing. To better serve our U.S. clients, we maintain an office in Cary, North Carolina, which facilitates the seamless shipping and receiving of materials from India. CiVentiChem is committed to delivering simple solutions to complex chemistry challenges across all phases of drug development.

CLAIRIgene is a preclinical stage biopharmaceutical company focused on development gene therapies for neurodegenerative diseases. Founded by innovative scientists with decades of experience, CLAIRIgene is committed to rapidly advancing their therapeutics to the clinic.

Clarus Biologics was launched to increase the availability of safe and effective prophylactic and therapeutic technologies. It’s lead product is a next-generation vaccine Virus Like Particle intended to enhance the effectiveness, efficiency and availability of vaccines.Clarus Biologics is Dedicated to the Discovery and Development of Novel Vaccine and Immunology Technologies

Cloud Pharmaceuticals is a pharmaceutical company that specializes in in silico therapeutics, revolutionizing drug discovery and development processes.

Codetta Bio is a company developing an integrated platform for highly multiplexed, quantitative, simultaneous multi-omic analyses of nucleic acid and protein assays. They are focused on precision medicine and accelerating clinical success through their advanced multi-omic biomarker measurement tools.

Cognosci is a healthcare company that focuses on improving patient care and outcomes through medical technology and health information.

Collaborations Pharmaceuticals, Inc. works on drug discovery for rare and neglected diseases. We develop and license our AI software as well as provide fee for services for pharmaceutical and consumer product services. To date we have won with collaborators $23.5M in grants since 2016.

Concentrx Pharmaceuticals, Inc. Management Team; Gilbert S. Mott, Jr.; Eric C. Richardson; W. James Alexander

CSL Plasma is one of the world’s largest collectors of human plasma. We are committed to excellence and innovation in everything we do. Our work ensures that tens of thousands of people with rare and serious diseases are able to live normal, healthy lives. We are committed to our work because people’s lives depend on us. See our community guidelines: https://bit.ly/2IApjpz. Supported by parent company CSL Behring, the global leader in plasma protein biotherapeutics, CSL Plasma has more than 280 plasma collection centers globally. CSL Plasma also has a state-of-the-art testing laboratory that features some of the most advanced technology, instrumentation and automation in the field; two logistics centers, one in Dallas and one in Indianapolis. Our corporate headquarters in Boca Raton, Florida. Our U.S. plasma collection centers are committed to the highest standards of quality and safety. When you donate, you give a valuable gift to those who require plasma-derived therapies to live healthier lives. The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 100 years experience in the development and manufacture of vaccines and plasma protein biotherapies. With major facilities in Australia, Germany, Switzerland and the US, CSL has over 30,000 employees working in more than 35 countries. See our community guidelines: https://bit.ly/3QZbZeZ

Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.

CytexOrtho was formed to develop and commercialize the tissue regeneration technology discoveries coming out of the lab of Dr. Farshid Guilak at Duke University. The original Cytex business plan received numerous innovation awards, including seed capital for the startup phase. Since its founding, Cytex has gone on to win numerous state and federal grants, each recognizing the novelty of the research and its enormous potential contribution to the clinical management of patients with osteoarthritis. The three Cytex co-founders form the core leadership of the company as it continues to develop its novel products.

With more than 20 years of industry experience and go to market expertise, Daily Manufacturing has set itself apart as a leader in helping businesses develop, create, and package products in the personal care, cosmetic, and health & wellness space. Our passionate team is committed to creating and delivering the highest-grade products possible without compromising on ingredients, packaging, or production techniques. Having seen rampant quality control and manufacturing issues in our industry, we set out to establish a best in class 45,000sq ft production facility located in Southern California, making products for global brands and small startups looking for a production partner they can trust and who can scale with their needs.

DHMRI is a 501(c)(3) non-profit, contract research organization specializing in the provision of cutting-edge genomic and metabolomic research services and instrumentation essential to furthering scientific understanding in areas including human health, nutrition, immuno-oncology, plant and animal trait development, and microbiome studies.The organization leverages its expertise and world-leading facilities through scientific collaborations with researchers and other non-profit organizations, world-wide, to deliver advancements in theknowledge and understanding of human wellness, health and longevity.As part of its mandate, DHMRI also provides an integrated core laboratory serving the North Carolina Research Campus (NCRC) and North Carolina university researchers, with cutting edge technologies, and services.

Duke University spin-out, Deep Blue Medical Advances has developed a novel hernia mesh to address the unacceptably high rate of hernia occurrence and recurrence. Millions of hernia surgeries are done globally with billions of dollars in clinical cost. Our surgeon-invented T-Line® Hernia Mesh with integral suture-like extensions is designed to eliminate a key point of failure for conventional mesh fixation - the mesh, suture, tissue interface - and to provide superior anchor strength. In addition, several additional products are in development, including an anchor clip for even faster, easier implantation; a biosynthetic version of the T-Line Hernia Mesh; and a coated composite version of the T-Line Mesh. Deep Blue products enhance hernia surgery with a potentially significant impact on the $1.1B global hernia device market. Due to its simple yet revolutionary design, the T-Line® Hernia Mesh has the potential to reduce hernia occurrence and recurrence by preventing or reducing mesh fixation failure.

Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal cord injured individuals.

DNAli is a biotechnology company that specializes in unlocking the full world of DNA through low-cost production of best-in-class DNA.

Domus Diagnostics is working to create infectious disease diagnostic tests that are affordable, user-friendly, accurate, and rapid enough to address the needs raised by current and future public health crises.

The Duke University Clinical Laboratoriesemploy a wide range of practices; from high-throughput, highly automated testing in their hematology, chemistry and immunoassay laboratories, to specialized mass spectrometry and molecular based testing in many of their subspecialty labs, to direct patient care bytransfusion services physicians. In total last year, their 850 clinical laboratorians deliveredover 10million resultsto support the care of the many hundreds of thousands of patients who came to Duke.In additional to supporting the clinical mission of DUHS, theyalso support the other two missions of theiracademic health care system: teaching and research.

Eldec Pharmaceuticals Inc. is a preclinical biotech company focused on developing novel peptide therapeutics to treat inflammatory and autoimmune diseases. The company was spun out of the University of North Carolina at Chapel Hill (UNC-CH) in 2017 and is currently developing peptide-based therapies to treat lung infections and lung inflammation.

Elo Life Systems is reimagining the future of food – focusing on ingredients that empower consumers to feel good about the food they eat every day. From unique plant-based sweeteners to saving crops like the banana from extinction, Elo harnesses the untapped potential of nature to make food tastier, healthier and resilient while requiring less from the planet.

Emergo Therapeutics: Bringing the Immune Response back into Balance

As the nation's leading environmental testing firm, EMSL's network of nationwide laboratories has been providing quality analytical services since 1981. We offer a wide array of analytical testing services to support environmental investigations focused on asbestos, microbiology, lead paint, environmental chemistry, indoor air quality, industrial hygiene and food testing. Additionally, we also provide materials testing, characterization, and forensic laboratory services for a wide range of commercial, industrial, regulatory, and law enforcement clients. Our unmatched capacity coupled with a company wide focus on customer satisfaction makes no project too large or too small. Our corporate research and development capabilities allow us to bring new methodologies on line quickly to meet new industry challenges and client needs. In recruiting and retaining talented and motivated scientists on a national scope, our expertise is marshaled throughout a nationwide network of analytical laboratories. We are committed to providing reliable, defensible data in a standardized and user-friendly format. Rapid turnaround and competitive prices make the dependable results you get that much more valuable. At EMSL, we're much more than another testing laboratory. We are your project partner!

Entegrion identifies, invents and systematically develops device and biological technologies to meet clearly defined medical needs. Our pipeline is distinguished by its uniqueness--- we pursue areas with limited competition and profound needs. We design efficient and focused development plans to assure that the products we deliver perform as intended and are ready for market. Twitter @entegrioninfo

A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers world-wide. Our technologies and products are making studies possible that were not imaginable just a few years ago. Our renowned chromatin researchers possess expertise and unique insight into chromatin biology and drug discovery that benefit our customers in ways other companies cannot. Epigenetics, the study of changes in heritable traits that occur independent of alterations in changes in the underlying DNA sequence, is an emerging and important area of biomedical research with broad impact on human health and disease.

Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat brain disorders. Serotonin synthesis amplification is distinct from targeting serotonin transporters (e.g., SSRIs) and receptors (e.g., psilocybin). Evecxia deploys 5-HTP, the natural serotonin precursor, delivered via proprietary drug delivery technologies to achieve sustained serotonin synthesis amplification. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression when first-line SSRI/SNRI antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy for patients in acute suicidal ideation crisis. Evecxia holds a comprehensive portfolio of issued and pending patents on the 5-HTP sustained-release/serotonin amplification method, doses, formulations, and related technologies.

Exela Pharma Sciences LLC is a specialty pharmaceutical company based in Lenoir, North Carolina, founded in 2005. The company develops, manufactures, and markets both generic and proprietary sterile injectable and ophthalmic products. Exela aims to improve patient outcomes and reduce healthcare costs through its innovative offerings. With a workforce of 501–1,000 employees, Exela specializes in products that face high barriers to market entry, utilizing regulatory pathways like Abbreviated New Drug Approvals (ANDA) and 505(b)(2) submissions. The company focuses on delivering high-quality, affordable products that enhance the experiences of healthcare providers and patients, emphasizing ease of use and clinical effectiveness. Exela's product range includes sterile injectables designed for improved safety and faster preparation, as well as sterile ophthalmic solutions that meet strict regulatory standards. The company operates a vertically integrated model, managing development, manufacturing, and commercialization in-house, which supports its commitment to quality control and innovation in the pharmaceutical industry.

EydisBio is a small biotech startup based out of Durham, NC focusing on the development of a platform of small molecule therapeutics targeting a variety of diseases driven by aberrant inflammatory/autoimmune processes.

Fennec Pharmaceuticals is a biotechnology company focused on improving the lives of children with cancer by addressing chemotherapy-induced hearing loss.

Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity in many patients, leaving many survivors of childhood cancer with permanent and irreversible hearing loss. Permanent hearing loss, even minimal, acquired at a young age has a devastating impact on development, education, and socialization and a lifelong negative impact on Quality of Life. There are no currently approved treatments for the prevention of platinum-induced hearing loss. At Fennec Pharmaceuticals, we are dedicated to the development of our investigational agent, PEDMARK™, for the prevention of ototoxicity in children, and we hope that this will enable more children to retain their hearing. In honor of our namesake, the fennec fox, we strive to embody adaptability and resourcefulness in everything we do. Please see www.fennecpharma.com for more information.

Focal Medical, Inc. is a privately held, biopharmaceutical company developing novel therapeutic products based on its innovative and patent protected targeted therapeutic system. The Company's lead product is a targeted therapeutic product delivering gemcitabine (an FDA approved chemotherapeutic) actively and directly to the pancreas by non-circulatory pathways to treat pancreatic cancer.

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of approximately 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com.

Frontier Scientific Solutions (FSS) is a contract service organization (CSO) which supports the life science industry by offering cGMP temperature-controlled storage, distribution, and logistic services. Drug development and commercialization require continuous temperature monitoring and control. Frontier's diverse offerings protect product integrity throughout the pharmaceutical supply chain. FSSs' validated software, cGMP storage and drug distribution facility, industry expertise and stringent quality standards support this objective throughout packaging, storage and distribution.

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer.

A leading herbal brand in North America, Gaia Herbs cultivates health and wellbeing by stewarding sustainable relationships between plants and people. Our unparalleled dedication to purity, integrity and potency is meticulously proven by science. We use organic methods from seed to shelf and pioneered the industry's first transparency program, MeetYourHerbs®. We are proudly based in the beautiful mountains of Western North Carolina.

We offer advanced diagnostic test solutions that GO BEYOND the limits of detection for low-abundance flea and tick-borne infections, such as bartonellosis and Lyme borreliosis. Our recently launched Nanotrap Urine test is a more sensitive direct detection test method for confirming Lyme disease diagnoses. Learn more on our website.

GeneCentric was founded based on intellectual property from Drs. Neil Hayes and Chuck Perou's laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine. GeneCentric currently has two unique platform technologies: The Lung Subtype Platform (LSP™) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP™ was licensed to and independently developed by Laboratory Corporation of America® Holdings ("LabCorp") and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. GeneCentric's second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the foremost clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies, GeneCentric can focus on its core strength, exceptional science and clinical studies, building evidence for the utility of its unique assays.

At GeneVentiv, we’re blazing a trail. We’re driven by curiosity. We’re fueled by learning expressed as innovation. Our mission is to discover, develop and deliver gene therapies for patients who had no hope of a cure – until now. We are founded on discovery bringing together insights into Adeno Associated Virus (AAV) directed gene therapy, Hemophilia and how to use the common pathway in the clotting cascade to surmount the obstacle of inhibitors. Patients with inhibitors are unable to respond to current therapies and gene therapies in development due to neutralizing antibodies (inhibitors) formed by the body in response to treatment with missing clotting factor. Our goal is to cure inhibitor patients with a single lifetime infusion, not to offer a half measure of weekly injections of a bypass agent.

Gilero offers end-to-end device design, development and contract manufacturing in the medical and pharmaceutical industries. Specializing in the areas of consumable and reusable medical devices, drug delivery, combination products and complex electromechanical systems, Gilero offers a wide range of services to meet your medical or drug delivery device needs.

Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. The antibody was isolated from patient’s B-cells using state of the art molecular genomic techniques. “GT103”, the company’s lead asset, is currently enrolling the first-in-man Phase 1 clinical trial in refractory NSCLC patients.

H&A Scientific, Inc. is a scientific software development firm specializing in pharmaceutical industry support. We develop, validate, and market quality computing systems for scientific data acquisition, processing, and data management. We have been creating programs for the laboratory since 1992. Our products have been designed under our Quality System to adhere to the current GAMP guidelines. We develop Quality Software products based on the needs of pharmaceutical companies subject to the constraints and compliance of the Food and Drug Administration (FDA). Our flagship product, SLIM, is a commercial off-the-shelf solution for total management of a company's drug stability program. Learn more about us: https://www.youtube.com/watch?v=_GZ9PQ9d4dI

HemoSonics is breaking new ground in point-of-care Viscoelastic #hemostasis testing. When time is critical, the Quantra® QPlus® System offers rapid, accurate, and easy to understand results that enable clinicians to make more informed #transfusion decisions, more quickly. This novel, cartridge-based POC VET system now has De Novo marketing authorization in the USA and is intended to assess the coagulation status of perioperative patients at the point of care. Follow us at @HemoSonics

The company is developing probiotics and enzymes that improve cattle health and digestive efficiency by eliminating methane.

Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

Hydromer® is a leading global surface modification and coatings solutions provider. As a trusted partner to companies worldwide, our solutions add value to our clients’ products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients’ needs. Hydromer collaborates extensively with clients to deliver superior, customized polymer-based solutions. We create or modify coating formulations that adhere to a multitude of substrates and match the unique requirements and geometries of any device. We are a leader in developing coating formulas and processes that meet a market-driven need for greener, more sustainable solutions. We offer custom industrial and medical device coatings, contract coating services, customized coating equipment, contract manufacturing, and turnkey operations backed by outstanding teams of research and development, customer service, and tech support. Hydromer® has been a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices for over 40 years. As a trusted partner to large and small companies worldwide, our solutions add value to our clients’ products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients’ needs. We are a GMP/ISO 13485 and ISO 9001 production facility located in Concord, North Carolina.

We are your worldwide manufacturer of quality polyclonal antibodies used in research and in vitro diagnostics. We have a wide range of secondary antibodies covering a broad spectrum of immunoglobulins from various species and cross absorbed to provide high specificity. We are also your source for primary polyclonal antibodies to hormones, cancer markers, cardiac markers and serum proteins. In addition to our product lines, we offer custom absorptons and purifications to meet specific requirements, yet knowledgeable and experienced to provide bulk manufacturing within cGMP guidelines and ISO quality systems requirements.

Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.

Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications and sometimes death.

Surgical software

Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases with unmet needs. Their pipeline includes drug candidates for celiac disease, NASH, Crohn's, and ulcerative colitis.

InSoma Bio is a company that borrows nature's own designs to develop unique products for reconstructive plastic surgery. Their product enables surgeons to use a person's own tissues to enhance the stability of autologous fat grafts and solve problems in tissue engineering and regenerative medicine.

IQVIA applies data science to the continuous advancement of human science to make health care decisions more precise, relevant, and even creative.

Isolere's mission is to increase global access to life-changing therapeutics and vaccines by offering novel purification reagents to alleviate manufacturing bottlenecks. The IsoTag™ reagents reimagine bioprocessing by combining target specific affinity ligands with phase separating biopolymers. The Affinity Liquid Phase Separation (ALPS) allows target biologics to be separated on the basis of affinity and size in a single process and can be implemented in a variety of techniques including microfiltration TFF and centrifugation processes. Isolere is currently developing purification solutions for adeno-associated virus (AAV), lentivirus (LV), adenovirus (AdV) and mRNA. Visit our website to learn more! Isolere Bio was acquired by Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, in February 2023.

Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.

Jellatech is a B2B biotech business based in Raleigh, NC producing human proteins for advancements in health using our unique cell-based technology. By unlocking the production of complex proteins at scale, Jellatech is enabling the creation of new possibilities for health and longevity, starting with Type I collagen. Jellatech’s mission is to revolutionize biomedical applications through cutting-edge, human-identical proteins. Jellatech enables advancements in tissue regeneration, injectable aesthetics, cell and gene therapy, and various therapeutic applications by supplying human-identical collagen and complex proteins. With all of it's known limitations, the tissue-extracted bovine and porcine medical grade collagen market for biomedical applications is expected to surpass $2.4B by 2032; however, with the introduction of a viable supply of human collagen across key verticals, the total addressable market (TAM) for human collagen alone could surpass $100-150 billion in the near future. Why Jellatech? Jellatech's platform is the only solution to deliver a reliable, consistent supply of bio-identical, fully functional human type I collagen for biomedical applications. Contact us to learn more. This is just the beginning. The potential is vast, and we’re here to help companies achieve breakthroughs in healthcare and beyond. Join us in unlocking a brighter future.

Great software in the right hands can change the world. We’ve seen it. You may have too. JMP products are behind many of the world’s greatest green-energy technologies, pharmaceutical breakthroughs, and high-tech improvements. For 30-plus years, JMP statistical software products have helped users see data clearly. It’s spelled J-M-P but pronounced “jump,” suggesting a leap in interactivity, a move in a new direction. Our purpose is to empower scientists and engineers via our statistical discovery software. Although our purpose is clearly connected to our software, it doesn’t end there. As an employer, JMP purposefully creates and maintains a culture of camaraderie that allows the personalities of our diverse and inclusive employee base to shine through. JMP is an equal opportunity employer. If you’re considering a career move, check out JMP Statistical Discovery. JMP employees live and work across the Americas, Europe, and Asia. Our business is growing, our employees are engaged, and our work is rewarding. JMP is a SAS company. Read more: www.jmp.com/about

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to our customers across geographies. We organize our business into two segments, namely, Specialty Pharmaceuticals, comprising Radiopharmaceuticals (including Radiopharmacies), Contract Manufacturing of Sterile Injectables and Non-sterile Products and Allergy Therapy Products, and Generics & APIs, comprising Solid Dosage Formulations and Active Pharmaceutical Ingredients.

KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 500+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. KBI is proud to be a JSR Life Sciences Company.

Keel Labs™ began in 2017 as AlgiKnit, creating ocean-focused materials built from renewable resources. In 2022, Keel Labs was established as a platform for innovation, broadening our vision for the potential of the ocean to accelerate our planet's development towards a more sustainable future. Driven by the exploration of novel resources from the ocean, Keel Labs™ functions as a hub for the next generation of climate-focused solutions derived from nature. So, though our name has changed, our mission remains the same: Keel Labs™ works at the nexus of design, science, and engineering to create impact-driven materials harnessing the power of the ocean.

KeraNetics is the global leader in keratin science, purified, human-derived keratin manufacture, research and development for healthier wound healing KeraNetics provides physicians with new options to help patients by exploiting the properties of purified, human-derived keratin. KeraStat® Cream: Better management of radiation dermatitis (RD). KeraStat® Cream harnesses the power of keratin proteins to support the management of dry, light, and moderately exuding partial thickness skin wounds such as radiation dermatitis resulting from a fractionated radiotherapy regimen. FDA cleared and available in 1 oz. and 5 mL tubes. Rx only.

Kinvard Bio is committed to developing a durable new class of antibiotics to treat the most challenging acute and chronic drug-resistant bacterial infections. Our chemistry platform technology is based on groundbreaking research that has been exclusively licensed from the Myers lab in the Department of Chemistry and Chemical Biology at Harvard University and funded by the Kineticos AMR Accelerator Fund I (KAMRA I). The oxepanoprolinamides (OPPs) represent a distinct class of lincosamide antibiotics that are pre-organized for highly effective and differentiated binding to the bacterial ribosome. In preclinical studies, OPPs have proven effective against both Gram-positive and Gram-negative bacterial pathogens associated with clinical needs that remain unmet.

KSE Scientific is a Bioprocess manufacturer specializing in the production of sterile products for the Tissue Banking, Pharmaceutical, and Biotech industries.

Kuria Therapeutics is a biopharmaceutical company that develops novel Nrf2 activators to treat blinding diseases.

Kymanox (‘ki-mah-noks'), meaning Ideal Knowledge Transfer, advances life science innovation through insightful solutions and collaboration. We do this by accelerating the design and commercialization of modern medicines for our customers using integrated engineering, scientific, compliance, and project management solutions that are insightful, collaborative, and comprehensive. By building and supporting the development of modern medicines, Kymanox has proven, end-to-end solutions that are helping bring better Life Science Products to the market- and keep it there. We do all of this with heart and pride… because patients deserve better. Kymanox, founded in 2004, serves clients from Fortune 100 companies to virtual start-up companies all across the globe. Headquartered in Research Triangle Park, NC, we have US offices in Boston and Philadelphia, and since 2022 have expanded to Germany, Switzerland, and Israel.

Levee Medical, Inc. designs, develops, and manufactures innovative urological devices with the focus of improving recovery outcomes post-prostatectomy so that patients can quickly and confidently return to normal activity. The company's inaugural product is designed to support and stabilize the post-operative bladder neck and urethra following prostatectomy to accelerate the return of continence and reduce the overall risk of chronic incontinence.

Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.

LigaTrap has developeda patented portfolio of affinity ligands that can be used to purifymonoclonal and polyclonal immunoglobulins from various species.

Lindy Biosciences is a development-stage protein therapeutic formulations company. Their core technology, Microglassification™, produces spherical, dense, stable particles of a therapeutic protein. These protein particles are ideal for long-term storage, or for incorporation into drug delivery formulations such as suspensions(for high-concentration delivery of antibodies), encapsulation (for sustained/controlled release), or dry powder pulmonary delivery.​

Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. Our proprietary PRINT technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. PRINT technology is a scalable cGMP compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. Liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. Liquidia is advancing product candidates from its own pipeline. These initial product candidates, LIQ861 and LIQ865, apply the PRINT technology to better drug delivery in inhaled and pain therapeutic areas, respectively. The PRINT technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA.

MacVector is a comprehensive Macintosh sequence analysis application that provides sequence editing, primer design, internet database searching, protein analysis, sequence confirmation, multiple sequence alignment, phylogenetic reconstruction, coding region analysis, agarose gel simulation and a variety of other functions.

Madera is the leader in highly potent and specific activators of the mitochondrial protease, ClpP. Together with our academic collaborators and the NIH/NCI, we have established the in vitro and in vivo performance of these agents. Notably, our agents provide a new mechanism of action that is effective on a number of drug-resistant cancer cells and patient-derived tissue samples. This technology is backed by the broadest patent portfolio in the area.

Marius Pharmaceuticals strives to better the lives of men and women by focusing on therapies designed for hypogonadism or Testosterone Deficiency. Our vision is to holistically improve metabolic health and mitigate significant unnecessary costs to the global healthcare system.

Marken is the clinical precision logistics and advanced therapy subsidiary of UPS Healthcare. The UPS Healthcare network consists of 200+ locations worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 46 locations worldwide, while maintaining the leading position for cell and gene therapy services, direct-to-patient and home healthcare services, biological sample shipments and biological kit production. Marken's dedicated 2,600+ staff members manage 200,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 17,500+ home healthcare visits. Additional services such as ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken's unique position in the pharma and logistics industry. Delivering What Matters From Clinical to Commercial.

Marc Clark is a medical research company that focuses on conducting clinical trials and providing resources for clinical trial volunteers.

Almost every factor that affects health – from genetics and the microbiome to disease and lifestyle – exerts its influence by altering metabolite levels in the body or other biological system. By producing the most accurate and comprehensive picture of the collection of metabolites, known as the metabolome, from a single biological sample, Metabolon can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of disease, medical intervention, diet or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers some of biology’s most difficult questions. Metabolon's unrivaled capability to look deep into the metabolome has enabled us to build the world’s largest library of compounds that currently includes 5,200+ total known molecules. Our proprietary Precision Metabolomics™ platform, combined with the world's most experienced metabolomics scientists, delivers biologic insights and identification of novel commercial opportunities for drug discovery and development, through clinical trials and life cycle management. Metabolon’s expertise is also accelerating research and product development for clients in academia, population health, consumer products, and nutrition industries. Founded in 2000 and based in Research Triangle Park, North Carolina, Metabolon has conducted more than 10,000 independent and collaborative studies, resulting in 2,000+ publications in leading peer-reviewed journals. For more information about our technology, products and services, please visit www.metabolon.com.

Metrics Contract Services is a North Carolina-based CDMO that offers services such as formulation development, analytical testing, and drug manufacturing for the pharmaceutical industry.

Mimetics is devoted to building and maintaining a world-class suite of analytical tools for investigating the dynamics of biological networks.

mPATH is a B2B software-as-a-service company that improves healthcare organizations' bottom line with an automated platform that closes preventive care gaps. mPATH™ is a low-cost, cloud-based program that identifies individuals who are overdue for routine screening tests, provides personalized education, and connects patients with needed care. We believe that healthcare shouldn't be confined to a doctor's office. With its cloud-based design, mPATH™ reaches patients wherever they are and when they want.

The global leader in continuous flow thermal sterilization. MTI Bioscience services the biotech, biopharmaceutical manufacturing, and biofuel industries for sterilization of growth media.

First in-class platform for harnessing the synergy between antibodies and mucus to reinforce the mucus barrier for mucosal health Proprietary intravaginal ring technologies for sustained delivery of small molecules to biomacromolecules Unparalleled safety from topical delivery

Nelum is a clinical stage biopharmaceutical company developing first in class and best in class patented molecules. Our area of focus is different forms of cancer. Our first drug, NLM-001, is a best in class small molecule hedgehog inhibitor currently in a phase Ib-IIa clinical trial in pancreatic cancer, after showing a safe profile in the Phase I trial.

Nitta Gelatin produces pharmaceutical and food-grade gelatin for a variety of uses in the pharmaceutical industry.

North Carolina Clinical Research (NCCR) is an independent, multi-therapeutic outpatient clinical research site located in Raleigh, North Carolina. NCCR has conducted Phase I, II, III and IV clinical trials in both children and adults since 1986. We have completed over 530 studies in a variety of therapeutic areas for many different pharmaceutical companies and Clinical Research Organizations (CROs). NCCR is dedicated 100% to Clinical Research. We have a dedicated staff that makes our facility stand out above the rest. Our hardworking, passionate, and friendly crew makes studies placed at NCCR a positive experience for both the sponsor and the patient. Supporting our principal investigators in the completion of each study is a clinical research staff of more than 18 professionals including Sub-Investigators, Site Manager, Subject Recruiter, Regulatory Administrator, Clinical Research Coordinator, and Office Coordinator. Our team has over 225 combined years of Clinical Research experience. Our facility is located across the street from a major medical center, and we have access to a metropolitan population exceeding one million. We are also located near three major universities: North Carolina State, Duke, and UNC-Chapel Hill. Our facility includes a fully equipped lab, secured storage for ambient and refrigerated study drug, a patient lounge area for extended days, and overnight facilities with showers and individual sleep areas.

Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Morrisville, North Carolina.

Founded by a team of accomplished industry professionals who began working together in 2000, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate significantly higher than the industry average. NovaQuest is actively evaluating and investing into global opportunities with financing needs that range from $30-100 million. For more information, please visit www.novaquest.com

Small Molecules

Supporting biotech companies from innovation to impact. Specialized clinical development solutions with dedicated teams. IQVIA Biotech is a CRO strategic problem-solver with therapeutic expertise.

Novex Innovations is a true CDMO (Contract Development/Manufacturing Organization) supporting our clients efforts in the commercialization of their products. Our areas of operation include: Biological Formulations Clinical Formulation Tissue Processing Bioengineered Tissue Active Pharmaceuticals Diagnostic Materials Medical Devices Development to Pre-Clinical to Commercial Regulatory Support Storage & Distribution & Order processing services. Scale-up optimization Product characterization Manufacturing through all phases of clinical trials Commercial modeling, manufacturing, and distribution Proof of concept Our clients range from single person operations to multinational companies. We provide process development, manufacturing, storage, and product distribution, all under cGMP procedures and policies. We operate cleanroom space at Class 1,000 and smaller scale spaces at Class 100, all for clinical and commercial manufacturing. Our Quality System is regularly monitored to the current ISO 13485 standards by BSI. Novex is also registered with the FDA. Our customers are both national and international and have a good understanding of other regulatory agencies as well. Customers have the option of storing their products at and having Novex ship on their behalf.

touchOPHTHALMOLOGY are a leading provider of learning resources, congress highlights and CME accredited activities for ophthalmologists.

Ofni Systems is an industry leader for 21 CFR Part 11 compliance and validation services. Their products for Part 11 compliant databases and spreadsheets are used by pharmaceutical, biotech and medical device companies across the globe, while its products for computer validation, auditing and FDA submissions ensure that their clients meet every requirement for electronic records and electronic signatures. The company provides live desktop support for superior customer support and training, and has been providing solutions to their clients since 1999. For more information, call (919) 844-2494 or visit http://www.OfniSystems.com.

OncoTAb, Inc., a North Carolina based biotechnology company, was founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The company has just launched its first product: Agkura™ Personal Score – a simple, non-invasive blood test that aids breast cancer detection in women with dense breast tissue. Roughly half of the women in the US have dense breast tissue and mammograms miss 50% of the breast cancers in these women, resulting in late stage diagnosis and mortality. Agkura™ Personal Score measures the biomarker tumor-associated MUC1 (tMUC1) and shows a trend of increasing value from benign disease through breast cancer stages 1 to 4. Women can monitor their personal score in conjunction with annual mammograms. A score above the normal range or an increase greater than normal variation will trigger a recommendation for diagnostic imaging (ultrasound or MRI), resulting in earlier stage diagnosis of breast cancer. The company is also working on developing treatments for breast and pancreatic cancers.

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company developing and commercializing therapies for the treatment of eye disorders.

Pairwise is a start-up food company that uses technology to break down the barriers that keep us from eating produce. At Pairwise, we are passionate about building a healthier world through better fruits and vegetables. Headquartered in Durham, NC, our team is made up of leaders in R&D, agriculture, and consumer products. Founded in 2017 and opened in 2018, Pairwise is working to deliver breakthrough innovation in agricultural sciences and in healthy consumer foods. Our team of proven leaders features Dr. Tom Adams, Chief Executive Officer (CEO), Dr. Haven Baker, Chief Business Officer (CBO), and eminent scientists Drs. Feng Zhang, David Liu and J. Keith Joung serve as advisors.

Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove any comments that do not adhere to our guidelines as well as report users who violate the rules of our page.

Parion Sciences is a development stage company dedicated to research, development, and commercialization of treatments to restore patient's innate mucosal surface defenses. In the eye and in the lung, our layer of protective mucus plays an important role in keeping our bodies healthy. Sometimes though, either through genetics, aging or environmental stimulus, our innate mucosal defense system can become compromised. Parion's science driven technologies target respiratory and ocular diseases in which the patient's ability to protect their mucosal surfaces is compromised.

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of advanced therapeutics that address unmet needs in the management of late-stage chronic kidney disease (CKD). Pathalys was created in partnership with Catalys Pacific and DaVita to become a multi-asset pharmaceutical company focused on the needs of patients with end-stage renal disease

Small Molecules

The mission of PharmaLogika is to provide quality services and the highest level of expertise to start-up as well as established industry leaders from discovery, through clinical trials, to commercialization of ideas. Our goals include the deployment and management of consulting teams utilizing our online products, while maintaining the lowest possible overhead cost structures. Our target audience is primarily but certainly not exclusively small to medium size businesses within the Pharmaceutical, Biotech, and Medical Device industries.

Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. In November 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. As of September 30, 2023, PMI's smoke-free products were available for sale in 82 markets, and PMI estimates that approximately 19.7 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products account for approximately 36.2% of PMI’s total third-quarter 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com. Our priority is to attract, support and keep with us diverse and unique individuals. Our global workforce of more than 69,000 people is one of our greatest strengths and the key to our success as a company. Our employees speak more than 80 languages and come from all corners of the world. PMI has also been certified as a “Global Top Employer” for the seventh consecutive year, in recognition of the high standards of excellence in our working environment and the exceptional development opportunities we offer. If you come into our offices or meet our people, you will quickly realize that at PMI everyone has the opportunity to make a difference and build phenomenal careers.

Phitonex uses a DNA nanotechnology platform to create highly customizable, deterministic fluorescent nanoparticles called Phitons.™

We are dedicated to creating innovative solutions for the most complex medical challenges, utilizing our unique approach to regenerative medicine. Protego-PD™ is a biologic with anti-inflammatory and immunomodulatory capabilities that work together to orchestrate a complex cellular response to restore and repair organs damaged by inflammation-driven diseases.

Plant Health Care is a leading provider of scientifically proven biological products for agriculture. The Company offers products to improve the health, vigor and yield of major field crops such as corn, soybeans, cotton and rice, as well as specialty crops such as fruits and vegetables. Our innovative line of patent protected products provides both economic and environmental benefits for our customers and capitalizes upon long-term trends towards natural systems and biological solutions to promote plant health and growth. Plant Health Care has global reach through operating subsidiaries and supply agreements with major industry an distribution partners.

Our goal is to replace cigarettes with our reduced-risk nicotine platform.

Polarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercializing innovative imaging solutions with its noninvasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.

Precise Bio develops and commercializes 4D bio-fabricated functional tissues and organs that can save lives and improve its quality. We combine world-class tissue-engineering and transplantation experience with best-in-class bio-printing, to create a scalable bio-fabrication platform, that can overcome current industry challenges and make complex human organs available for transplantation.

Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer and infectious diseases.

Precision provides full sample management services in our Biological Freezers and Pharmaceutical stability chambers with four facilities across the United States. Our cGMP facilities (Wilson, NC; Hopedale, MA; Fort Lauderdale, FL; and El Segundo, CA) include the following features: • All Freezers, rooms, and Ambient Storage are fully validated. • 24/7/365 monitored Fire Alarm and Security system. • Access restricted with keyed access to main building, storage area, and individual chambers. Access doors are alarmed and camera monitored. • 21 CFR, Part 11 compliant monitoring system recording conditions with calibrated probes on all rooms/freezers. System does remote notification to alert personnel of alarms during non-business hours. • Backup generator to power the entire facility if there is a power outage, plus back-up conditioners/freezers are on hand if needed. Conditions available: Long-Term and Intermediate conditions of 25°C/40%Rh, 25°C/60%Rh, 30°C/65%Rh, 30°C/75%Rh, 30°C/35%Rh Accelerated storage of 40°C/not more than (NMT) 25%Rh, 40°C/75%Rh Refrigerated and Freezer storage conditions of 2°C - 8°C (5°C), -20°C, -80°C, LN2 Ambient storage conditions of 15°C - 30°C

Premier Nutrition Company (PNC) is one of the fastest-growing companies in the convenient nutrition space showing clear leadership in the category of protein shakes and protein powders. We make the brands Premier Protein, Dymatize, and PowerBar (which is sold internationally), and we are part of our holding company, BellRing Brands (NYSE: BRBR). We have a simple, yet powerful, formula for our success, which we've been nailing for over 15 years. We start with an organization powered by our company purpose—Changing Lives with Good Energy. Then our purpose-driven people are given the support and autonomy to develop and grow. Next, we are super-intentional about designing a culture where everyone feels like they truly connect and belong, which is one of our five company core values. Purpose-driven, connected employees who are consistently mastering new skills deliver amazing business results. Winning companies with amazing people and thriving cultures attract and retain top talent, so the cycle becomes self-reinforcing or what we call our regenerative culture. We don't mind sharing our formula since, as people who we believe in the power of changing lives with good energy, we think the world would be a better place if more workplaces treated adults like adults and gave them the platform to do the best work of their lives—alongside some truly amazing colleagues. Why don't more companies do this? It takes deep-in-your-bones conviction to your people, products, and purpose to pull it off. The results speak for themselves: We're certified as a Great Place to Work™ for the 7th year-running in 2023. We take care of our people, but here are some crowd-pleasers: Year-round ½ day Fridays, in-office massages, free lunches & snacks, dogs in the office, month-long cultural and diversity celebrations, monthly over-the-top in-office events, generous paid family leave regardless of gender, all positions bonus-eligible, and coaching conversations vs performance reviews.

Premier Research, a global clinical research, product development, and consulting company, is dedicated to helping innovators transform life-changing ideas and breakthrough science into new medical treatments. We offer strategic solutions across the entire development lifecycle, from pre-clinical through commercialization, specializing in smart study design and full-service clinical trial management. Leveraging technology and therapeutic expertise, we deliver clean, conclusive data with a focus on reducing development timelines, securing access to the right patients, and effectively navigating global regulations to ensure submission-ready results. As an organization that puts patients first, we pride ourselves on helping customers answer the unmet needs of patients across a broad range of medical conditions. Are you ready to make a real difference and help us transform this exciting industry? Follow our company page for more information about us and the work we do, and check out our current openings for your next career move!

We are a fully integrated pharmaceutical company located in Cranbury, engaged in developing and sales & marketing of generic pharmaceutical products in North American and South American markets. Since launching our first product, Benazepril in 2010, we have launched 11 products in U.S. market. Through reliable products’ quality, manufacturing capability and competitively strategic API resources from China, we have successfully reduced the medical cost for American buyers and help millions of patients against their illness.

Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the greatest morbidity and mortality. We are developing oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications, unlocking new treatment options for patients who are underserved by existing therapies.

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

We're a small but rapidly growing neurotechnology company based in Durham, North Carolina. Our vision is to enable and support outstanding basic and translational neuroscience research through innovative and affordable products. We launched XCSITE 100, our tDCS/tACS research solution, in 2016. Today, XCSITE 100 is used in leading brain stimulation labs across the United States. We are actively developing new technology and working with our stakeholders to provide new research solutions to enable cutting edge neuroscience.

Qualicaps manufactures empty two-piece capsules (gelatin and hypromellose) and encapsulation equipment under cGMP regulations for use by pharmaceutical, OTC and dietary-supplement manufacturers.

Rainbow Company Youth Theatre is a nationally acclaimed, award-winning youth theatre group funded by the city of Las Vegas. For more than 45 years, the Rainbow Company has been providing quality theatre experiences for young people and their families.

From Molecule to Market: Your Trusted Partner... Raybow USA (formerly PharmAgra) in Brevard, North Carolina, is a division of Jiuzhou Pharmaceutical, a CDMO with headquarters in Linhai, Taizhou City, in Zhejiang Province, China. Raybow USA, with over 20 years in R&D and Analytical Chemistry, is now your gateway to global power. Your big idea can start small and then fluidly scale up to medium, large, or super-sized production –all with the same North Carolina connections you’ve come to expect. Jiuzhou Pharma understands that bringing a molecule to market is not just about chemistry—it’s about trust, collaboration, and expertise. With years of proven excellence in the CDMO space, Jiuzhou Pharma has become a global leader in small molecule, nucleotide and peptide development. Raybow USA can help take your vision from concept to commercial reality—quickly, efficiently, and with the utmost precision. Let’s work together to shape the future of health! Why Jiuzhou Pharma? ✔ Comprehensive Solutions: support for your molecules from early-stage R&D to full-scale commercial manufacturing ✔ Expertise: deep scientific knowledge to deliver innovative and efficient solutions for small molecule and Tides CDMO services ✔ Global Reach, Local Focus: European and American subsidiaries tailor global CDMO services for specific regional markets ✔ Customer-Centric: committed to your success through partnerships based on transparency, reliability, and shared goals ###

Redbud Labs develops affordable microfluidic technologies that reduce lab workflow complexity without sacrificing performance. We have developed NAxtract, a cartridge-based automated sample preparation platform that sets the bar for ease-of-use. Reagents are contained in a single, disposable cartridge, capable of processing 8 samples in 30 minutes. This platform disrupts the sample prep market by making automation accessible: small footprint, zero overhead, no setup, no service contracts. Our first cartridge performs pathogen extraction from human biofluids. The platform will feature a menu of cartridges, making NAxtract is the most reliable and affordable sample prep solution available across a range of markets including liquid biopsy, infectious disease diagnostics, and genomic surveillance. At the core of our cartridges is a microfluidic agitation technology that overcomes diffusion-driven fluid dynamics at the microscale. Our patented Redbud Post technology enables microfluidic sample prep up to 1000x faster than conventional on-cartridge methods. Our intellectual property portfolio includes patents (18 granted, 36 pending), trade secrets, and exclusive supply. Redbud Labs headquarters, located in the Research Triangle Park, North Carolina is home to a nearly 8,000 sq.ft. custom-built lab space dedicated to production, prototyping, and general lab applications. Redbud Labs has dedicated BSL-2 facilities for cell culture, biological applications, and sample preparation with approximately 450 sq. ft. lab space isolated from shop and production at Redbud Labs headquarters. Redbud is certified ISO 9001 and 45001 for its quality, health and safety management system

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

restor3d enables surgeons to improve the reconstruction and repair of the human body through 3D printed implants with enhanced anatomical fit and superior integrative properties. Leveraging expertise and experience in 3D printing of key biomedical materials spanning a wide range of properties, restor3d seeks to improve medical device solutions.

The Rose Research Center multisite clinical research company under the direction of Jed E. Rose, Ph.D. Dr. Rose has a legacy of societal influence by way of co-inventing the nicotine skin patch and other treatments for smoking cessation. His primary research goals are to elucidate the biological mechanisms underlying tobacco addiction and to promote the development of more effective treatments. The Rose Research Center operates two premier research facilities in North Carolina, leading the way in clinical trials to eliminate smoking addiction. RRC specializes in product innovation, product development, pharmaceutical testing and development, and cessation and addiction research. Facilities: Two offices, both over 2000sq ft. located in Raleigh and Charlotte, North Carolina. Full time Research Coordinators and technicians at both locations alongside M.D.'s and P.A.'s specifically trained in research. Participation: 10,000 subjects in a proprietary database and a reach to nearly 5M individuals in N.C. RRC utilizes advanced in-house marketing techniques to recruit. Successful recruitment strategies are formulated and executed by our marketing department using television commercials, print advertising, social media, and a powerful set of recruitment websites. Standard Equipment: Emergency AED and on-site portable oxygen, ECG machines, Carbon monoxide monitors, Breathalyzer, Pulse oximeters, Clinical freezer storage (-86°C/-20°C) with 24-hour power backup and temperature monitoring, Compact analytical balance, High-pressure programmable syringe pumps for device and cigarette testing, Refrigerated centrifuge, Nebulizer, CReSS smoking topography, Medical exam tables, Laboratories equipped for clinical trial specimen collection and processing, Isolation negative pressure room and telescopic ventilation arm for smoking studies adjacent to a second room with a telescopic ventilation arm, Video recording and two-way audio monitoring of subject sessions.

We know the HPA-T Axis Sanesco Health International is a biomedical company providing licensed healthcare practitioners with innovative, evidence-based and clinically-effective solutions. Assessing, monitoring and correcting neurotransmitter and hormone imbalances is not just what we do, it's ALL we do. We believe in identifying the underlying root causes behind symptoms and conditions affecting HPA-T Axis function. We offer a specialized, clinical model to help health care practitioners see each patient holistically on a neuroendocrine level, and to guide their patients on a healthier path. Sanesco's Communication System Management clinical model includes: -non-invasive functional laboratory testing -personalized patient-centered reporting -all-natural nutritional formulas Our team's clinical expertise, on-staff clinician support, complimentary interpretations, education and hands-on training mean better results for practitioners and their patients. The reason why we choose to specialize in optimizing HPA-T Axis function is because of the pivotal role it plays in the body's Communication System as a whole. Upstream biochemical imbalances found in the critical messengers of this axis can contribute to the manifestation of cognitive function issues, mood disorders and other symptoms and conditions such as: depression, anxiety, insomnia or sleep concerns, Alzheimer's, dementia and memory loss, impairments of focus and attention, PTSD, weight issues, metabolic syndrome, blood sugar regulation, diabetes, chronic pain, fibromyalgia, chronic fatigue, sexual health, menopause, autism, ADD/ADHD, and addictions. Optimizing function of the HPA-T Axis has a positive effect on the rest of the neuroendocrine system and balancing the body's Communication System as a whole. This creates our clinical model which is key to addressing a plethora of symptoms and conditions, and optimizing health and overall quality of life. Privacy Policy https://sanescohealth.com/terms-privacy/

Sapere Bio is a longevity technology company. SapereX, a blood-based measure of cellular senescence and immune function, captures fundamental mechanisms of aging. SapereX allows clinicians and scientists to see early aging and monitor how interventions aimed to increase healthspan are working in individual patients. We are changing the way aging is measured and imagined, for longer healthspan and better lives. Sapere Bio was co-founded by Dr. Norman Sharpless, former Director of the NCI, and Dr Natalia Mitin, current CEO of Sapere Bio.

Scorpius Holdings Inc., through its Scorpius BioManufacturing subsidiary, is an integrated contract development and manufacturing organization dedicated to transparent collaboration and flexible, high-quality biologics. With an experienced team and new, purpose-built U.S. facilities, Scorpius Holdings Inc. is committed to excellence in large molecule cGMP manufacturing.

Sequence Inc. provides turn-key consulting solutions and services for the biopharmaceutical manufacturing industry with a focus on Commissioning, Qualification and Validation (CQV) and Digital Solutions for facilities, utilities, equipment, computerized systems and labs. Through a fully functional, mock pharmaceutical manufacturing training facility, consultants are trained in a hands-on environment that is unique in the industry that includes both equipment and software. Founded in 2002, Sequence provides consulting solutions to clients across the U.S. and parts of Europe. The company is headquartered in the heart of RTP in Morrisville, NC with a second hub in Framingham, MA.

Our mission is to provide the next generation of sound medicine through proven ablative technologies that precisely deliver care while sparing healthy tissue. This next generation of care involves expanding our current HIFU technologies to treat a range of urological indications that balance treatment effectiveness and quality of life.

Spencer Health Solutions (www.spencerhealthsolutions.com) is transforming healthcare by moving care delivery to the home through the company's spencer® medication adherence and engagement platform. The spencer FDA Class I technology enables virtual care by connecting patients, clinicians, pharmacists, and family members digitally.

Spyryx Biosciences is a biopharmaceutical company developing inhaled therapeutics for severe respiratory diseases, with Cystic Fibrosis (CF) as the first target indication. Our development efforts are based on novel peptides that reduce the airway surface density of epithelial sodium channels (ENaC) via ligand-mediated internalization. This mechanism has a robust and durable effect on enhancing airway and mucus hydration to promote mucociliary clearance. We believe the mechanism of our investigational peptides has the potential to provide disease-modification for the dehydration associated lung disease that is a feature of CF, as well as having utility in multiple other pulmonary and non-pulmonary indications. Spyryx's lead program, SPX-101, has successfully completed a Phase 1 safety study in healthy volunteers and is now being tested in a multinational Phase 2 study in individuals living with CF. The Phase 2, entitled "Hydration for Optimal Pulmonary Effectiveness"​ or HOPE-1, is a 28-day, placebo-controlled study intended to establish treatment proof of concept independent of CFTR mutation (www.clinicaltrials.gov/NCT03229252). This study has initiated recruitment in select sites in Canada and Western Europe. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com.

Stat One is a Contract Research Organization (CRO) providing expert consulting and statistical support for pharmaceutical, biotechnology, and medical device clinical trials. Our expertise is supported by three decades of industry and regulatory experience in the areas of statistical consulting, reporting, and data management. We emphasize efficiency and effectiveness when preparing your product for FDA approval. Stat One's experience covers a broad range of therapeutic areas and indications. Our team is your partner in growing a better future!

Sterling Pharmaceutical Services LLC is a full-service pharmaceutical contract manufacturer and formulation development expert that specializes in technology transfers, scale-up, and commercial manufacturing.

Swabbot is an automated swabbing device that perfects the swabbing process by improving consistency, recovery, cost and safety.

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D-959 and has initiated pre-clinical studies in Huntington’s Disease models.

Techverse, Inc. is a contract research and development firm in advanced energy generation and utilization concepts with a focus on improving energy efficiency.Techverse, Inc. is developing a membrane filtration-based algae dewatering process to produce algae paste.

Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need.

Tethis creates plant-based, compostable superabsorbents and rheology modifiers for use in hygiene, personal care, packaging, tissue & towel, energy, agriculture, and water treatment industries. Tethis allows companies to bring more sustainable products to market.

Torque Bio is an ambitious newly launched biotechnology start-up leveraging the power of an innovative technology platform for the treatment of disease. We believe our science represents a novel class of versatile, tunable, and persistent therapeutics that have the potential to transform the development of new medicines.

The company is working to improve the characteristeristics of trees.

TregTherapeutics Inc. is a preclinical stage company focused on the treatment and cure of multiple sclerosis. The objective of the TregTherapeutics tolerogenic vaccine is to reverse the inflammatory T cell immune attack in demyelinating lesions of an MS patient, and subsequently, to create an anti-inflammatory tolerogenic response within that patient.

Triangle Insights Group is a strategy consulting firm that delivers high-impact solutions to clients in the life sciences industry.

The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.

One of the leading cancer centers in the nation, UNC Lineberger Comprehensive Cancer Center is located in Chapel Hill, North Carolina. UNC Lineberger is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers and was rated as exceptional - the highest category - following its most recent NCI review. The center brings together some of the most exceptional physicians and scientists in the country to focus on advancing the prevention, early detection and treatment of cancer. With research that spans the spectrum from the laboratory to the bedside to the community, UNC Lineberger faculty work to understand the causes of cancer at the genetic and environmental levels, to conduct groundbreaking laboratory research, and to translate findings into pioneering and innovative clinical trials.

The Biotechnology Research and Training Center (BRTC) has the mission to stimulate the transformation of knowledge through coordinated efforts into increased economic well-being of southeast North Carolina.

Monoclonal Antibody

Vast is a preclinical airway immunology company focused on breaking the vicious cycle of infection and chronic inflammation in respiratory diseases. The Vast technology platform begins with the unmatched antimicrobial activity of nitric oxide in the form of stable prodrugs. When our new chemical entities are combined with inhalation formulation expertise and proprietary chemistry for delivering drug candidates to the lungs, the result is aerosolized therapies targeting the specific needs of individual patient populations. Nitric oxide is an endogenous molecule that plays a vital role in the natural immune system response to microbial pathogens. Taking cues from human physiology, our nitric oxide based “antibiotic alternative” compounds are not susceptible to antimicrobial resistance mechanisms common to traditional antibiotics.

Velocity is the world’s leading organization of fully integrated clinical research sites. With 90 sites and more than 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and wellbeing. Velocity offers unified research site solutions to efficiently provide the right patients, investigators, and research staff for clinical trials across the U.S. and Europe. The company also operates a technology hub in India, where it is unlocking a new era in clinical research by developing innovative systems to leverage expansive site, patient, and historical performance data. To learn more about how Velocity delivers high-quality data, exemplary patient care, and unprecedented efficiency for clinical trials at any scale, visit VelocityClinical.com.

Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients. Headquartered in Cary, North Carolina, USA, Veloxis is focused on the global development and commercialization of medications utilized by transplant patients and by patients with serious related diseases. We know what transplant means to patients, and we’re leading innovation to improve their experience. For patients, transplant is a life-changing procedure. But changes come with challenges. At Veloxis, our mission is to see and respond to the challenges along the transplant journey.

Villaris Therapeutics is a preclinical-stage biopharmaceutical company focused on developing novel antibody therapeutics for the treatment of vitiligo. A recent discovery revealed that an immune pathway, initiated by IL-15 signaling and its formation of autoimmune memory T cells (TRM), was responsible for the return of vitiligo usually soon after stopping treatments. Targeting this pathway therapeutically was very effective at reversing the disease in a mouse model of vitiligo with long-lasting results. Villaris Therapeutics is developing a novel humanized anti-IL-15R antibody to target depletion of TRM for the effective and durable treatment of vitiligo and other tissue-specific autoimmune diseases that also involve these cells.

vTv Therapeutics is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv and its development partners are pursuing additional indications, including type 2 diabetes and other chronic conditions.

The Wake Forest Institute for Regenerative Medicine is working to grow tissues and organs and develop healing cell therapies for more than 30 different areas of the body, from kidney and trachea to cartilage and lung.

M3 Wake Research is a premier clinical trial network that has been conducting studies since 1984. With over 30 years of experience, the network's subject database for clinical trial participants has substantial potential and continues to expand as we grow our network across the country. The network comprises of premier investigational sites that are fully integrated and designed to deliver superior clinical trial experiences to patients, sponsors, and CROs. M3 Wake Research offers a full range of clinical trial services, from study design to study completion, to meet the needs of global biopharmaceutical, biotechnology, medical device, and pharmaceutical industry leaders. The board-certified physicians of M3 Wake Research have successfully completed over 7,000 clinical trials with integrity, human protection, and expeditious delivery of accurate evaluable data. Experience M3 Wake Research's uncompromising approach to superior quality in planning and executing each study according to regulations. The network consistently exceeds sponsor expectations for integrity, subject enrollment, human protection, and expeditious delivery of accurate evaluable data. Choose M3 Wake Research for clinical trials that meet and exceed your expectations.

White Labs provides yeast supplies, lab services and consulting to breweries, wineries and distilleries.

About Worldwide Clinical Trials  Worldwide Clinical Trials is a leading full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new treatments. Our capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by our team members who bring their expertise and a collaborative, personalized approach to each clinical program. Anchored in our company’s scientific heritage, our dedicated therapeutic focus on cardiovascular, metabolic, neuroscience, oncology, and rare diseases, is applied to develop flexible plans and solve problems quickly for our customers. Our talented team of 3,000+ professionals spans 60+ countries, and embraces a culture of diversity, equity, inclusion, and belonging (DEI&B). We are united in cause with our customers to improve the lives of patients through new, innovative therapies. For more information on Worldwide, visit www.Worldwide.com.

Developing next generation technologies for precision medicine and drug discovery.

ZenBio is a provider of advanced cell-based solutions and services to the life science, cosmetics, and personal care communities, specializing in adipose derived stem cells and human primary cells.

ZY Therapeutics is a biotechnology company that develops novel therapeutics for oncology treatments.